L’intervento di prostatectomia radicale robotica consiste nell’asportazione completa della prostata per via laparoscopica, con l’impiego del sistema robotico DaVinci®. La tecnica robotica consente di operare con un ingrandimento visivo di circa 20 volte e con una visione a 3 dimensioni, consentendo di eseguire l’intervento con una accuratezza significativamente superiore a quello della chirurgia a cielo aperto o della chirurgia laparoscopica classica.
Di seguito sono riportati alcuni degli articoli scientifici pubblicati dal dr. Umberto Capitanio nell'ambito del tumore della prostata (Fonte: Pubmed-Scopus Luglio 2013):
Capitanio U, Suardi N, Briganti A, Gallina A, Abdollah F, Lughezzani G,Salonia A, Freschi M, Montorsi F. Influence of obesity on tumour volume inpatients with prostate cancer.
BJU Int. 2012 Mar;109(5):678-84. doi:10.1111/j.1464-410X.2011.10453.x. Epub 2011 Jul 20. PubMed PMID: 21777363.
Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F,Montironi R. The importance of interaction between urologists and pathologists inincidental prostate
cancer management. Eur Urol. 2011 Jul;60(1):75-7. doi:10.1016/j.eururo.2011.03.012. Epub 2011 Mar 16. Erratum in: Eur Urol. 2012Aug;62(2):e47. PubMed PMID: 21444149.
Capitanio U. Contemporary management of patients with T1a and T1b prostatecancer. Curr Opin Urol. 2011 May;21(3):252-6. doi: 10.1097/MOU.0b013e328344e4ad. Review. PubMed
PMID: 21358335.
Capitanio U, Suardi N. Prostate cancer in 2010: GSU: misclassification orbiological progression? Nat Rev Urol. 2011 Feb;8(2):65-6. doi:10.1038/nrurol.2010.247. Review. PubMed
PMID: 21304540.
Capitanio U, Briganti A, Suardi N, Gallina A, Salonia A, Freschi M, Rigatti P,Montorsi F. When should we expect no residual tumor (pT0) once we submitincidental T1a-b prostate
cancers to radical prostatectomy? Int J Urol. 2011Feb;18(2):148-53. doi: 10.1111/j.1442-2042.2010.02689.x. Epub 2010 Dec 30. PubMedPMID: 21198944.
Capitanio U, Pellucchi F, Gallina A, Briganti A, Suardi N, Salonia A, AbdollahF, Di Trapani E, Jeldres C, Cestari A, Karakiewicz PI, Montorsi F. How can wepredict lymphorrhoea
and clinically significant lymphocoeles after radicalprostatectomy and pelvic lymphadenectomy? Clinical implications. BJU Int. 2011Apr;107(7):1095-101. doi: 10.1111/j.1464-410X.2010.09580.x. Epub
2010 Sep 29.PubMed PMID: 20880192.
Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C,Shariat SF, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI.Population-based analysis of normal
Total PSA and percentage of free/Total PSAvalues: results from screening cohort. Urology. 2009 Jun;73(6):1323-7. doi:10.1016/j.urology.2008.10.026. Epub 2009 Apr 18. PubMed PMID: 19376563.
Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F. Biopsy corenumber represents
one of foremost predictors of clinically significant gleasonsum upgrading in patients with low-risk prostate cancer. Urology. 2009May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009
Feb 4. PubMedPMID: 19195695.
Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, Shariat SF, Duclos A, Arjane P, Montorsi F, Karakiewicz PI. Effect of body mass index onprostate-specific antigen
and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men. Int J Urol. 2009Jan;16(1):91-5. doi: 10.1111/j.1442-2042.2008.02192.x. Epub 2008
Nov 27. PubMedPMID: 19054167.
Capitanio U, Ahyai S, Graefen M, Jeldres C, Shariat SF, Erbersdobler A,Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Péloquin F, Pharand D,Arjane P, Huland H, Karakiewicz
PI. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. Urology.2008 Dec;72(6):1208-11; discussion 1212-3. doi:
10.1016/j.urology.2008.04.053.Epub 2008 Aug 9. PubMed PMID: 18692880.
Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Salonia A, Cestari A,Guazzoni G, Rigatti P, Montorsi F. Suspected clinical T3 prostate cancer isassociated with a high rate of
negative extended biopsies: clinical implications.Eur Urol. 2009 Jan;55(1):253-4. doi: 10.1016/j.eururo.2008.05.025. Epub 2008 May 22. PubMed PMID: 18513849.
Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, ColomboR, Karakiewicz PI, Rigatti P, Montorsi F. Radical prostatectomy for incidental(stage T1a-T1b)
prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol. 2008 Jul;54(1):118-25. doi:10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26. PubMed PMID:
18314255.